- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02008435
Increasing the Effectiveness of the Diabetes Prevention Program
March 20, 2018 updated by: Barbel Knauper, McGill University
Increasing the Effectiveness of the Diabetes Prevention Program Through If-then Plans and Mental Practice: A Parallel Randomized Trial
The Diabetes Prevention Program (DPP) is highly effective in promoting weight loss in overweight and obese individuals (e.g., 7% average loss of body weight), and thereby reducing the risk of developing weight-related health consequences.
One-on-one DPP sessions, however, are costly and the group-delivered DPP version, the Group Lifestyle Balance program (GLB), is less effective (4% average loss of body weight).
The aim of this two-arm parallel randomized controlled trial is to increase the effectiveness of the GLB by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
The study will provide evidence-based data on the effectiveness of an enhanced GLB intervention in promoting weight loss and in reducing weight-related risk factors for chronic health problems.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Please see brief summary.
Study Type
Interventional
Enrollment (Actual)
172
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1B1
- McGill University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- men and women
- ages of 18 and 75
- overweight or obese (BMI 28-45 kg/m2)
- sedentary (< 200 min/week of moderate or vigorous exercise)
- waist circumference of >= 88cm for women and >= 102cm for men
Exclusion Criteria:
- diabetes (hemoglobin A1c < 7.0%).
- taking the medication metformin (used for treating pre-diabetes or diabetes)
- having been pregnant in the past 6 months or planning on becoming pregnant in the next 2 years
- currently undergoing treatment for cancer
- using medication that affects body weight (e.g., loop diuretics)
- being unable to participate in regular moderate physical activity
- having severe uncontrolled hypertension (> 190/100mm Hg)
- being unable to communicate in English or French
- being diagnosed with bulimia nervosa, currently active major depression, or other severe psychiatric disease (including dementia);
- suffering from a heart attack, stroke, or heart failure within the past 6 months
- experiencing excessive weight loss (more than 10 pounds or 4.54 kilograms) in the past 3 months
- currently participating in another weight loss program
- having had bariatric surgery in the past 2 years or plans on getting it in the near future
- planning on moving away from Montreal within the next year
- having another member of one's household enrolled in the program.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Enriched GLB
This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
|
Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
Other Names:
|
|
Active Comparator: Standard GLB
This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
|
This arm is the standard Group Lifestyle Balance program
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent body weight loss
Time Frame: 3 months after beginning of the intervention
|
The primary outcome will be percent body weight loss from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months after beginning of the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent body weight loss
Time Frame: 12 months
|
Percent body weight loss 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
|
Percent body weight loss
Time Frame: 24 months
|
Percent body weight loss 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
|
Personal weight loss goal
Time Frame: 3 months
|
Reaching percent body weight loss goal (7% of body weight) from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months
|
|
Personal weight loss goal
Time Frame: 12 months
|
Reaching percent body weight loss goal (7% of body weight) 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
|
Personal weight loss goal
Time Frame: 24 months
|
Reaching percent body weight loss goal (7% of body weight) 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
|
Personal exercise goal
Time Frame: 3 months
|
Reaching exercise goal (150 min/week) from baseline to 3 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
3 months
|
|
Personal exercise goal
Time Frame: 12 months
|
Reaching exercise goal (150 min/week) 12 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
12 months
|
|
Personal exercise goal
Time Frame: 24 months
|
Reaching exercise goal (150 min/week) 24 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
24 months
|
|
Waist circumference
Time Frame: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Waist circumference
Time Frame: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Waist circumference
Time Frame: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Hemoglobin A1c levels
Time Frame: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Hemoglobin A1c levels
Time Frame: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Hemoglobin A1c levels
Time Frame: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Blood pressure
Time Frame: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Blood pressure
Time Frame: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Blood pressure
Time Frame: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Total cholesterol/HDL ratio
Time Frame: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Total cholesterol/HDL ratio
Time Frame: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Total cholesterol/HDL ratio
Time Frame: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Physical activity duration
Time Frame: 3 months
|
Total minutes per week.
|
3 months
|
|
Physical activity duration
Time Frame: 12 months
|
Total minutes per week.
|
12 months
|
|
Physical activity duration
Time Frame: 24 months
|
Total minutes per week.
|
24 months
|
|
Number of steps taken per week
Time Frame: 3 months
|
Steps taken per week, recorded using a pedometer.
|
3 months
|
|
Number of steps taken per week
Time Frame: 12 months
|
Steps taken per week, recorded using a pedometer.
|
12 months
|
|
Number of steps taken per week
Time Frame: 24 months
|
Steps taken per week, recorded using a pedometer.
|
24 months
|
|
Exercise stress test (EST)
Time Frame: 3 months
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-Report Index of Habit Strength
Time Frame: 3 months
|
Self-monitoring and behaviors
|
3 months
|
|
Self-Report Index of Habit Strength
Time Frame: 12 months
|
Self-monitoring and behaviors
|
12 months
|
|
Self-Report Index of Habit Strength
Time Frame: 24 months
|
Self-monitoring and behaviors
|
24 months
|
|
Habit formation indices of weight tracking
Time Frame: 3 months
|
Frequency of weight tracking.
|
3 months
|
|
Habit formation indices of weight tracking
Time Frame: 12 months
|
Frequency of weight tracking.
|
12 months
|
|
Habit formation indices of weight tracking
Time Frame: 24 months
|
Frequency of weight tracking.
|
24 months
|
|
Habit formation indices of physical activity tracking
Time Frame: 3 months
|
Frequency of physical activity tracking.
|
3 months
|
|
Habit formation indices of physical activity tracking
Time Frame: 12 months
|
Frequency of physical activity tracking.
|
12 months
|
|
Habit formation indices of physical activity tracking
Time Frame: 24 months
|
Frequency of physical activity tracking.
|
24 months
|
|
Habit formation indices of fat grams and calorie tracking
Time Frame: 3 months
|
Frequency of food tracking.
|
3 months
|
|
Habit formation indices of fat grams and calorie tracking
Time Frame: 12 months
|
Frequency of food tracking.
|
12 months
|
|
Habit formation indices of fat grams and calorie tracking
Time Frame: 24 months
|
Frequency of food tracking.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ilka Lowensteyn, PhD, McGill University
- Study Director: Lawrence Joseph, PhD, McGill University
- Study Director: Aleksandra Luszczynska, PhD, University of Colorado, Denver
- Study Director: Steven Grover, MD, McGill University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Knauper B, Shireen H, Carriere K, Frayn M, Ivanova E, Xu Z, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The effects of if-then plans on weight loss: results of the 24-month follow-up of the McGill CHIP Healthy Weight Program randomized controlled trial. Trials. 2020 Jan 7;21(1):40. doi: 10.1186/s13063-019-4014-z.
- Knauper B, Carriere K, Frayn M, Ivanova E, Xu Z, Ames-Bull A, Islam F, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The Effects of If-Then Plans on Weight Loss: Results of the McGill CHIP Healthy Weight Program Randomized Controlled Trial. Obesity (Silver Spring). 2018 Aug;26(8):1285-1295. doi: 10.1002/oby.22226. Epub 2018 Jun 28.
- Knauper B, Ivanova E, Xu Z, Chamandy M, Lowensteyn I, Joseph L, Luszczynska A, Grover S. Increasing the effectiveness of the Diabetes Prevention Program through if-then plans: study protocol for the randomized controlled trial of the McGill CHIP Healthy Weight Program. BMC Public Health. 2014 May 18;14:470. doi: 10.1186/1471-2458-14-470.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2013
Primary Completion (Actual)
December 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
December 6, 2013
First Submitted That Met QC Criteria
December 6, 2013
First Posted (Estimate)
December 11, 2013
Study Record Updates
Last Update Posted (Actual)
March 21, 2018
Last Update Submitted That Met QC Criteria
March 20, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOP-123242
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Enriched GLB
-
Hangzhou GluBio Pharmaceutical Co., Ltd.RecruitingNon-Hodgkin LymphomaChina
-
GluBio Therapeutics Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic SyndromesUnited States
-
University of PittsburghUnited States Department of DefenseCompletedMetabolic Syndrome | PrediabetesUnited States
-
University of PittsburghCompletedQuality of Life | Obesity | Physical Activity | Diet Modification | Cardiovascular Risk Factor | Mobility Limitation | Eating Behavior
-
Hangzhou GluBio Pharmaceutical Co., Ltd.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid MalignancyChina
-
Lovoria WilliamsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting
-
Ohio State UniversityCompleted
-
University of PittsburghRobert C. Atkins FoundationCompleted
-
Baylor Research InstituteCompletedObesity | Weight Loss | Diet Modification | Spinal Cord InjuriesUnited States
-
Baylor Research InstituteCompletedHypertension | Risk Reduction Behavior | African Americans | Diet, Carbohydrate-RestrictedUnited States